Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease
- 30 June 2008
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 30 (3), 293-302
- https://doi.org/10.1016/j.nbd.2008.01.014
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences of the United States of America, 2007
- Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell modelNeurobiology of Disease, 2005
- Magnetic resonance imaging at microscopic resolution reveals subtle morphological changes in a mouse model of dopaminergic hyperfunctionNeuroImage, 2005
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- A cell-based screen for drugs to treat Huntington's diseaseNeurobiology of Disease, 2004
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004
- Recent Advances on the Pathogenesis of Huntington's DiseaseExperimental Neurology, 1999
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Selective neurodegeneration in Huntington's diseaseAnnals of Neurology, 1995
- Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's diseaseAnnals of Neurology, 1992